LUND, Sweden, March 4, 2019 /PRNewswire/ -- Immunovia has today
published the annual report for 2018 in Swedish. It is available on
Immunovia's website.
Mats Grahn, CEO, comments: "We
entered 2018 with the continued mission to develop and validate
accurate blood-based diagnostic tests and moved towards the
exciting activities to commercialize those efforts. We completed
the expansion of our production and sample testing facilities,
IMMray™ Dx Laboratories, at our headquarters in Lund, Sweden, we advanced our important
clinical collaborations and entered into new ones, our shares began
trading on Nasdaq Stockholm main list and embarked on a new and
inspiring initiative to partner with several prominent patient
organizations to sponsor fundraising walks to help build awareness
of the IMMray™ PanCan-d test and educate on the risk factors and
the symptoms for pancreatic cancer."
Major highlights include:
- Trading of Immunovia's shares was approved for transfer to
Nasdaq Stockholm's Main Market. Immunovia carried out a directed
new share issue of approximately SEK 324
million.
- The Journal of Clinical Oncology published the results of the
retrospective clinical validation study conducted by Swedish,
Danish and American researchers. The study showed that IMMray™
PanCan-d serum biomarker microarray detects early pancreatic cancer
with 96 percent accuracy.
- At the beginning of the year, the Spanish University Hospital
in Santiago de Compostela joined
as new partner in Immunovia's global prospective validation study
PanFAM-1 to validate Immunovia's bloodbased test, IMMray™ PanCan-d.
Other collaborating partners that were added during the year were
Massachusetts General Hospital, NYU School of Medicine, University
Hospital in Linköping, Karolinska
Institutet and the Spanish University Hospital Clínica
Universidad de Navarra. Another four
North American clinics targeting hereditary pancreatic cancer
(FPC), McGill, Yale, and the
universities of Pennsylvania and
Massachusetts, joined Immunovia's
prospective PanFAM-1 study.
- Immunovia signed a letter of intent for a collaboration on a
pancreatic cancer study of diabetic patients with the Danish Center
for Strategic Research in Type 2 Diabetes (DD2). The intention is
that the DD2 center will participate in the pioneering prospective
study PanDIA-1, which examines type-2 diabetics over the age of 50
and the risk that these will develop pancreatic cancer.
- Immunovia's biomarker signature, IMMray™ PanCan-d, for the
diagnosis of pancreatic cancer received patents in Japan.
- Immunovia announced that the IMMray™ platform can distinguish
non-small cell lung cancer from healthy controls with 95 percent
accuracy according to a study conducted in collaboration with a
global top 10 pharmaceutical company.
- New data emerged that show that the sampling collection routine
that applies commercially and for Immunovia's final validation
studies affects the product's algorithms. Immunovia therefore
decided to optimize IMMray™ PanCan-d to ensure the quality of the
test response before release.
- Immunovia published a new study confirming that the blood-based
IMMray™ test successfully addresses one of the major challenges of
autoimmune testing. The study, which was conducted in collaboration
with Linköping University, showed that IMMray™ technology can
identify patients with rheumatoid arthritis (RA), even though these
have tested negative for antibodies against cyclic citrated
peptides (CCP).
- Immunovia's clinical study PanFAM-1 was registered at
ClinicalTrials.gov, the world's largest database for clinical
studies.
- Based on the promising results of previous discovery studies,
Immunovia decided to add a strategic focus of IMMray™ blood-based
biomarker signatures for rheumatoid arthritis.
- Immunovia completed the expansion of the production and sample
testing facilities, IMMray™ Dx Laboratories, at their headquarters
in Lund, Sweden. This new
state-of-the-art facility, working in conjunction with our IMMray™
Dx Laboratories at our subsidiary in Marlborough, USA, allows for the capacity and capability to
produce slides to not only meet the current foreseen demands for
commercial testing but at the same time meet the demands of the
large prospective studies.
The Swedish annual report is available on Immunovia's website:
https://immunovia.com/investors/financial-reports/ and is also
attached below.
For more information, please contact:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood-based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases diagnosis,
prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-publishes-the-annual-report-for-the-financial-year-2018,c2755598
The following files are available for download:
https://mb.cision.com/Main/13121/2755598/1001515.pdf
|
Immunovia Annual
Report 2018 Swedish version
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-publishes-the-annual-report-for-the-financial-year-2018-300805699.html
SOURCE Immunovia AB